At visit 3, there were still 131 patients on treatment.
The mean IOP was 17.5 (+/- 3.6) mmHg (range: 10 - 30) at baseline, 17.4 (+/- 4.2) mmHg (range: 8 - 40) at visit 2, and 18.2 (+/- 4.3) mmHg (range: 10 - 37) at visit 3. The difference was not clinically significant.
The mean change from baseline was -0.1 (+/- 4.2) mmHg at visit 2 and -0.3 (+/- 7.7) mmHg at visit 3.
Among treatment completers, the IOP decreased in 35.8%, increased in 40.5%, and did not change from baseline in 22.9%.
Clinical success was not influences by any baseline factor.
Three per cent of patients discontinued treatment due to adverse events before visit 2, while 4% discontinued before visit 3. This left 131 patients in the study sample.
No unexpected adverse events occurred.
The percentage of patients with adverse events was 42% at baseline, 50% at visit 2 and 42% at visit 3.
Of the percentages of patients who had adverse events at visits 2 and 3, 12% (visit 2) and 13% (visit 3) of such events were attributed to brimonidine.
For quality of life factors, the average scores at visits 1, 2 and 3, respectively were:
for comfort, 3.6 (+/- 1.0), 3.6 (+/- 1.1) and 3.7 (+/- 1.2);
for convenience, 3 (+/- 1), 4.1 (+/- 1.1) and 4.1 (+/- 1.3);
for change in vision, 3.5 (+/- 1), 3.2 (+/- 0.8) and 3.2 (+/- 1.1);
for ease of remembering, 3.2 (+/- 1), 3.9 (+/- 1) and 3.8 (+/- 1.3); and
for satisfaction, 3.4 (+/- 1.1), 4.1 (+/- 1.1) and 3.9 (+/- 1.3).
Therefore, with the exception of change in vision, where a slight worsening was observed, monotherapy led to improvements in all quality of life factors.
Overall, 77% of study completers (71% of the initial study sample) remained on brimonidine therapy. Investigators recommended that 95% of patients with a decreased or unchanged IOP at visit 3 continue to take brimonidine. This represented the success rate of brimonidine.